Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
|
Outline of Final Research Achievements |
Each compound strongly caused concentration-dependent cytocidal effect. IC50 value of trinuclear compound is superior to cisplatin, and both complexes showed caffeine potentiation. Two novel platinum do not show cross resistance to cisplatin. Apoptosis induction and acetylation of histon H2AX were observed. In vivo, 1Pt showed almost same, 3Pt showed stronger antitumor effect compared to cisplatin.Two novel platinum complexes that we developed showed strong ant-tumor effect in osteosarcoma in vitro and in vivo. 3Pt shows superior anti-tumor effect compared to cisplatin. 1Pt shows strong in vivo anti-tumor activity. Apoptosis is induced by DNA double strand break. Novel platinum compounds may overcome cisplatin resistance.
|